# US 10,441,631 B2 · Therapeutic agent for amniotic fluid embolism > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,441,631 B2 - Document ID: US10441631B2 - Status: Granted - Kind: B2 - Application number: 14/771,090 - Filed: 2014-02-28 - Published: 2016-01-14 - Granted: 2019-10-15 - Earliest claimed: 2013-02-28 - Assignees: CSL Behring GmbH - Applicants: Csl Behring GmbH - Inventors: Naohiro Kanayama; Tomoaki Ikeda; Madoka Furuhashi - Web page: https://patentgrep.com/patent/US10441631B2 ## CPC - A61K 38/1709: {from mammals} - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)} - A61P 11/00: Drugs for disorders of the respiratory system - A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention relates to a therapeutic agent for amniotic fluid embolism (AFE). Furthermore, the present invention relates to a therapeutic agent for AFE comprising a C1-inhibitor, particularly a human plasma-derived C1-inhibitor. ## Claims ### Claim 1 A method for the treatment of amniotic fluid embolism comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition including human plasma-derived C1 esterase inhibitor to treat amniotic fluid embolism, wherein the pharmaceutical composition comprises human plasma-derived C1 esterase inhibitor in a concentration higher than that present in normal human plasma, wherein the human plasma-derived C1 esterase inhibitor is administered as the sole active compound. ### Claim 2 (depends on 1) The method according to claim 1, wherein the human plasma-derived C1 esterase inhibitor is administered intravenously or subcutaneously. ### Claim 3 (depends on 1) The method according to claim 1, wherein the human plasma-derived C1 esterase inhibitor is administered in a dose of 1 to 1000 units per kg body weight. ### Claim 4 (depends on 1) The method according to claim 1, wherein the human plasma-derived C1 esterase inhibitor is administered in a single dose as an injection or as an infusion. ### Claim 5 (depends on 1) The method according to claim 1, wherein the human plasma-derived C1 esterase inhibitor is administered within 2 hours after the onset of clinically potential amniotic fluid embolism. ### Claim 6 (depends on 1) The method according to claim 1, wherein the human plasma-derived C1 esterase inhibitor is administered in a dose of 5 to 500 units per kg body weight. ### Claim 7 (depends on 1) The method according to claim 1, wherein the human plasma-derived C1 esterase inhibitor is administered in two doses, each as an injection or as an infusion. ### Claim 8 (depends on 1) The method according to claim 1, wherein the human plasma-derived C1 esterase inhibitor is administered in multiple doses, each as an injection or as an infusion. ### Claim 9 (depends on 1) The method according to claim 1, wherein the human plasma-derived C1 esterase inhibitor is administered as a long term infusion or application. ### Claim 10 (depends on 1) The method according to claim 1, wherein the human plasma-derived C1 esterase inhibitor is administered within 1 hour after the onset of clinically potential amniotic fluid embolism. ### Claim 11 (depends on 1) The method according to claim 1, wherein the human plasma-derived C1 esterase inhibitor is administered within 30 minutes after the onset of clinically potential amniotic fluid embolism. ### Claim 12 (depends on 1) The method according to claim 1, wherein the human plasma-derived C1 esterase inhibitor is administered directly after the onset of clinically potential amniotic fluid embolism. ### Claim 13 (depends on 1) The method according to claim 1, wherein the pharmaceutical composition includes human plasma-derived C1 esterase inhibitor in a concentration at least 50 times higher than that present in normal human plasma. ### Claim 14 (depends on 1) The method according to claim 1, wherein the human plasma-derived C1 esterase inhibitor is administered intravenously. ### Claim 15 (depends on 14) The method according to claim 14, wherein the human plasma-derived C1 esterase inhibitor is administered in a dose of 10 to 200 units per kg body weight. ### Claim 16 A method for treatment of amniotic fluid embolism comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition including human plasma derived C1 esterase inhibitor to treat amniotic fluid embolism, wherein the pharmaceutical composition comprises human plasma derived C1 esterase inhibitor in a concentration higher than that present in normal human plasma, and wherein the human plasma derived C1 esterase inhibitor is administered within 3 hours after the onset of clinically potential amniotic fluid embolism, wherein the human plasma derived C1 esterase inhibitor is administered as the sole active compound. ### Claim 17 A method for treatment of amniotic fluid embolism comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition including recombinant human C1 esterase inhibitor to treat amniotic fluid embolism, wherein the pharmaceutical composition comprises recombinant human C1 esterase inhibitor in a concentration higher than that present in normal human plasma, wherein the recombinant human C1 esterase inhibitor is administered as the sole active compound. ### Claim 18 (depends on 17) The method according to claim 17, wherein the recombinant human C1 esterase inhibitor is administered within 3 hours after the onset of clinically potential amniotic fluid embolism. ### Claim 19 (depends on 1) The method according to claim 1, wherein the human plasma-derived C1 esterase inhibitor is administered as a monotherapy. ### Claim 20 (depends on 16) The method according to claim 16, wherein the human plasma-derived C1 esterase inhibitor is administered as a monotherapy. ### Claim 21 (depends on 17) The method according to claim 17, wherein the recombinant human C1 esterase inhibitor is administered as a monotherapy.